• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

参与东非药品监管协调倡议的各当局审评模式及审批时限评估:协调一致及未来推进策略

Evaluation of the review models and approval timelines of authorities participating in the East African Medicine Regulatory Harmonisation initiative: alignment and strategies for moving forward.

作者信息

Ngum Nancy, Ndomondo-Sigonda Margareth, Habonimana Rémy, Siyoi Fred, Irasabwa Clarisse, Ojukwu Julia, Apolinary Felchism, Okello Andrew, Ahmada Sabrina, Walker Stuart, Salek Sam

机构信息

Department of Clinical and Pharmaceutical Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.

African Union Development Agency-New Partnership for Africa's Development, Johannesburg, South Africa.

出版信息

Front Med (Lausanne). 2024 Sep 17;11:1438041. doi: 10.3389/fmed.2024.1438041. eCollection 2024.

DOI:10.3389/fmed.2024.1438041
PMID:39355848
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11442268/
Abstract

INTRODUCTION

Medicines regulatory harmonisation has been embraced by many national regulatory authorities (NRAs) to improve public health through faster availability of safe, high-quality, and effective medical products to patients and enhanced standardisation of technical guidelines and work sharing, leading to reduced cost to pharmaceutical companies. After ten years of implementing regulatory harmonisation by the East African Community Medicines Registration Harmonization (EAC-MRH) initiative, it is now imperative for participating NRAs to rely on each other to minimise duplication of use of limited resources. Major challenges in implementing reliance are the lack of clear registration processes and delays in the approval. The aim of this study was to compare review models, target timelines and data requirements used in assessing applications by EAC-MRH NRAs so as to align and propose strategies for improvement.

METHODS

A validated questionnaire that standardises and captures review processes was completed by the head of the medicine's registration division in each of the seven EAC-MRH NRAs. A country report based on the completed questionnaire was developed for each NRA and validated by the heads of the respective authorities.

RESULTS

Most applications received by all countries were for generics except Kenya, which received a significant number of new active substance applications (55 and 53 in 2020 and 2021). Mean approval times for generics using full review varied, with Tanzania's time declining for the three years. Target timelines for full review for the five countries ranged between 180 calendar days (Tanzania) to the highest 330 days (Zanzibar). The three countries (Kenya, Rwanda and Uganda) utilising the verification review model had a target timeline of 90 days. All six authorities conducted abridged reviews and fast-track assessments through a priority review track. The common technical document format was mandatory for applications in all authorities. The target timeline for key milestones in the review process varied for each country with a few similarities.

DISCUSSION

The study has provided a baseline for review models, target timelines and data requirements utilised in assessing applications for registration by EAC-MRH NRAs. Implementing the recommendations from this study will enable the NRAs to align and improve their registration processes.

摘要

引言

许多国家药品监管机构(NRAs)都采用了药品监管协调措施,以通过更快地为患者提供安全、高质量和有效的医疗产品来改善公众健康,并加强技术指南的标准化和工作共享,从而降低制药公司的成本。在东非共同体药品注册协调(EAC-MRH)倡议实施监管协调十年后,参与的国家药品监管机构现在必须相互依赖,以尽量减少对有限资源的重复使用。实施相互依赖的主要挑战是缺乏明确的注册流程和审批延迟。本研究的目的是比较EAC-MRH国家药品监管机构在评估申请时使用的审查模式、目标时间线和数据要求,以便进行调整并提出改进策略。

方法

由七个EAC-MRH国家药品监管机构中每个机构的药品注册部门负责人完成一份经过验证的问卷,该问卷用于规范和记录审查流程。根据填写完成的问卷为每个国家药品监管机构编写一份国家报告,并由各自机构的负责人进行验证。

结果

除肯尼亚外,所有国家收到的大多数申请都是仿制药申请,肯尼亚在2020年和2021年收到了大量新活性物质申请(分别为55份和53份)。采用全面审查的仿制药平均批准时间各不相同,坦桑尼亚的时间在三年中有所下降。五个国家全面审查的目标时间线从180个日历日(坦桑尼亚)到最长的330天(桑给巴尔)不等。采用核查审查模式的三个国家(肯尼亚、卢旺达和乌干达)的目标时间线为90天。所有六个机构都通过优先审查通道进行简化审查和快速评估。通用技术文档格式对所有机构的申请都是强制性的。审查过程中关键里程碑的目标时间线因每个国家而异,有一些相似之处。

讨论

该研究为EAC-MRH国家药品监管机构在评估注册申请时使用的审查模式、目标时间线和数据要求提供了一个基线。实施本研究的建议将使国家药品监管机构能够调整并改进其注册流程。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d57b/11442268/68825bf03c7b/fmed-11-1438041-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d57b/11442268/d8fbba6bdba3/fmed-11-1438041-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d57b/11442268/68825bf03c7b/fmed-11-1438041-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d57b/11442268/d8fbba6bdba3/fmed-11-1438041-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d57b/11442268/68825bf03c7b/fmed-11-1438041-g002.jpg

相似文献

1
Evaluation of the review models and approval timelines of authorities participating in the East African Medicine Regulatory Harmonisation initiative: alignment and strategies for moving forward.参与东非药品监管协调倡议的各当局审评模式及审批时限评估:协调一致及未来推进策略
Front Med (Lausanne). 2024 Sep 17;11:1438041. doi: 10.3389/fmed.2024.1438041. eCollection 2024.
2
Evaluation of good review practices in member authorities of the East African Medicines Regulatory Harmonisation initiative: strategies for alignment with African medicines agency.评估东非药品监管协调倡议成员国当局的良好审评实践:与非洲药品管理局保持一致的策略
Front Med (Lausanne). 2024 Aug 29;11:1437970. doi: 10.3389/fmed.2024.1437970. eCollection 2024.
3
Evaluation of the Review Models and Approval Timelines of Countries Participating in the Southern African Development Community: Alignment and Strategies for Moving Forward.对参与南部非洲发展共同体国家的审查模式和审批时间表的评估:协调与推进战略
Front Med (Lausanne). 2021 Aug 27;8:742200. doi: 10.3389/fmed.2021.742200. eCollection 2021.
4
Evaluation of the effectiveness and efficiency of the East African community joint assessment procedure by pharmaceutical companies: Opportunities for improvement.制药公司对东非共同体联合评估程序的有效性和效率评估:改进机会
Front Pharmacol. 2022 Nov 3;13:1031289. doi: 10.3389/fphar.2022.1031289. eCollection 2022.
5
Evaluation of the Effectiveness and Efficiency of the East African Community Joint Assessment Procedure by Member Countries: The Way Forward.东非共同体成员国对联合评估程序有效性和效率的评估:前进之路
Front Pharmacol. 2022 Jul 5;13:891506. doi: 10.3389/fphar.2022.891506. eCollection 2022.
6
Regulatory performance of the East African Community joint assessment procedure: The way forward for regulatory systems strengthening.东非共同体联合评估程序的监管绩效:加强监管系统的未来之路。
Regul Toxicol Pharmacol. 2023 May;140:105383. doi: 10.1016/j.yrtph.2023.105383. Epub 2023 Mar 16.
7
What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvements.联合评估程序对创新产业具有吸引力的因素:成功之处、挑战及改进建议。
Front Med (Lausanne). 2023 Sep 4;10:1207954. doi: 10.3389/fmed.2023.1207954. eCollection 2023.
8
Assessment of the effectiveness and efficiency of the economic community of West African States Medicines Regulatory Harmonization initiative by the pharmaceutical industry.制药行业对西非国家经济共同体药品监管协调倡议的有效性和效率评估。
Front Pharmacol. 2023 May 9;14:1184108. doi: 10.3389/fphar.2023.1184108. eCollection 2023.
9
Comparison of Three Regional Medicines Regulatory Harmonisation Initiatives in Africa: Opportunities for Improvement and Alignment.比较非洲的三种区域药品监管协调倡议:改进和统一的机会。
Int J Health Policy Manag. 2024;13:8070. doi: 10.34172/ijhpm.2024.8070. Epub 2024 May 5.
10
Regional regulatory harmonisation initiatives: Their potential contribution to the newly established African Medicines Agency.区域监管协调倡议:对新成立的非洲药品管理局的潜在贡献。
Regul Toxicol Pharmacol. 2023 Dec;145:105497. doi: 10.1016/j.yrtph.2023.105497. Epub 2023 Sep 29.

引用本文的文献

1
Comparison of the review models and regulatory timelines of seven countries participating in the ECOWAS-MRH initiative: identifying opportunities for improvement.参与西非国家经济共同体-疟疾研究与培训联盟倡议的七个国家的审评模式和监管时间表比较:确定改进机会
Front Med (Lausanne). 2025 Jul 14;12:1587761. doi: 10.3389/fmed.2025.1587761. eCollection 2025.
2
Strengthening Vaccine Regulation: Insights from COVID-19 Vaccines, Best Practices, and Lessons for Future Public Health Emergencies.加强疫苗监管:来自新冠疫苗的见解、最佳实践及对未来突发公共卫生事件的启示
Vaccines (Basel). 2025 Jun 12;13(6):638. doi: 10.3390/vaccines13060638.
3

本文引用的文献

1
Evaluation of Risk-Based Approaches to the Registration of Medicines: Current Status Among African Regulatory Authorities.基于风险的药品注册方法评估:非洲监管机构的现状。
Pharmaceut Med. 2023 May;37(3):251-260. doi: 10.1007/s40290-023-00472-0. Epub 2023 Apr 19.
2
Evaluation of the effectiveness and efficiency of the East African community joint assessment procedure by pharmaceutical companies: Opportunities for improvement.制药公司对东非共同体联合评估程序的有效性和效率评估:改进机会
Front Pharmacol. 2022 Nov 3;13:1031289. doi: 10.3389/fphar.2022.1031289. eCollection 2022.
3
Evaluation of the Review Models and Approval Timelines of Countries Participating in the Southern African Development Community: Alignment and Strategies for Moving Forward.
Advancing Regulatory Oversight of Medical Device Trials to Align with Clinical Drug Standards in the European Union.
推进欧盟医疗器械试验的监管监督,使其与临床药物标准保持一致。
Pharmaceuticals (Basel). 2025 Jun 12;18(6):876. doi: 10.3390/ph18060876.
4
Suggested Improvements to the Current East African Community Medicines Regulatory Harmonization Joint Review Process and a Proposed New Review Model for this Initiative.对当前东非共同体药品监管协调联合审查程序的建议改进以及该倡议的新审查模式提案。
Pharmaceut Med. 2025 Mar;39(2):125-141. doi: 10.1007/s40290-025-00554-1. Epub 2025 Mar 4.
对参与南部非洲发展共同体国家的审查模式和审批时间表的评估:协调与推进战略
Front Med (Lausanne). 2021 Aug 27;8:742200. doi: 10.3389/fmed.2021.742200. eCollection 2021.
4
An Overview of the Drug Registration Requirements for Export to Tanzania, Nepal, and Cambodia.向坦桑尼亚、尼泊尔和柬埔寨出口的药品注册要求概述。
Ther Innov Regul Sci. 2020 Jan;54(1):171-176. doi: 10.1007/s43441-019-00042-0. Epub 2020 Jan 6.
5
Access to medicines through health systems in low- and middle-income countries.中低收入国家通过卫生系统获得药品。
Health Policy Plan. 2019 Dec 1;34(Supplement_3):iii1-iii3. doi: 10.1093/heapol/czz119.